Rua Bioscience Limited

Overview

Rua is a New Zealand pharmaceutical company that is aiming to be a leading producer of cannabinoid derived medicines. The Company was established in 2017 in part to support local economic development in the Tairāwhiti (East Coast) region, and is a pioneer in the New Zealand medicinal cannabis sector. It was the first company in New Zealand to obtain a licence to cultivate cannabis for research purposes and the Company’s co-founder was actively involved in both the establishment of the key industry association and the development of the regulatory framework that is now in place to govern the sector. Rua will operate in the research, cultivation, extraction and manufacturing parts of the medicinal cannabis supply chain.

Performance

The following information has been extracted from Rua Bioscience Limited's Full Year Results, released on 28 August 2026:

Rua Bioscience releases preliminary annual results – unaudited

Rua Bioscience reports strong FY26 revenue growth Customer revenue increases 71% as international strategy gains momentum

Kei te piki te kaha o Rua, kua tipu nga piuta, kua heke nga utunga. Kua toro nga ringa o te kamupene ki nga makete o Tiamana, Ahitereiria, Czechia me te UK, a kei te tipu tonu te makete ki Aotearoa nei.

Revenue from customers increased 71% year on year as Rua continued to execute its export-led growth strategy. The company strengthened its position in established markets including Australia and Germany, expanded its presence in the United Kingdom and Czechia, entered Canada, and continued to grow in its home market of Aotearoa New Zealand.

FY26 milestones

• Increased revenue from customers by 71% to $2.58 million.

• Secured Rua’s largest export agreement to date, a United Kingdom sales and distribution agreement expected to generate more than NZ$10 million in revenue over its initial two-year term.

• Strengthened commercial relationships with leading clinic chains in Australia.

• Expanded Rua’s product portfolio in Aotearoa New Zealand, supporting continued revenue and market-share growth.

• Completed Rua’s first export of live cannabis clones to Canada, establishing a platform for the future commercialisation of Rua’s unique genetics in one of the world’s largest cannabis markets.

• Raised $2.3 million of new shareholder capital to strengthen commercial operations and support continued execution of Rua’s strategy.